The DOI matches its Crossref record; 112 of the 113 references it cites were found in a registry or an index.
The Old and the New: Prospects for Non-Integrating Lentiviral Vector Technology
Open accessAbstract
Lentiviral vectors have been developed and used in multiple gene and cell therapy applications. One of their main advantages over other vectors is the ability to integrate the genetic material into the genome of the host. However, this can also be a disadvantage as it may lead to insertional mutagenesis. To address this, non-integrating lentiviral vectors (NILVs) were developed. To generate NILVs, it is possible to introduce mutations in the viral enzyme integrase and/or mutations on the viral DNA recognised by integrase (the attachment sites). NILVs are able to stably express transgenes from episomal DNA in non-dividing cells or transiently if the target cells divide. It has been shown that these vectors are able to transduce multiple cell types and tissues. These characteristics make NILVs ideal vectors to use in vaccination and immunotherapies, among other applications. They also open future prospects for NILVs as tools for the delivery of CRISPR/Cas9 components, a recent revolutionary technology now widely used for gene editing and repair.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This also prevents the provirus formation while the vector DNA remains one of the primary episome types [10].”
From Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“NILVs were optimised and modified to increase the transgene expression and to improvise the safety profile [10].”
From Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through (2022) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“NILVs can stably express transgenes from the episomal DNA in non-dividing cells or transiently if the target cells divide both in vitro and in vivo.”
From Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through (2022) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903 · cited 2×
“Lentiviral vectors have been derived from human immunodeficiency virus-1 (HIV-1) and developed by segregating the necessary genetic information to form an infectious particle in different plasmids, while removing the capability for replication [1].”
BackgroundMethodLMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
A Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341 · cited 1×
“In the last generation of these vectors, the regulatory protein Rev was removed from the packaging plasmid and coded from a fourth, distinct plasmid [3].”
BackgroundGene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167 · cited 2×
“In fact, there were several adverse events detected in clinical trials, later described, due to insertional mutagenesis [11,12].”
BackgroundMultiply attenuated lentiviral vector achieves efficient gene delivery in vivo
Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., & Trono, D. (1997) · Nature Biotechnology · doi:10.1038/nbt0997-871 · Cited by 1,977 · cited 1×
“Earlier vector generations used three plasmids for vector production: the packaging plasmid that codes for all necessary viral proteins for the particle formation and delivery of the transgene into target cells, the envelope plasmid coding for a glycoprotein that allows for the recognition of target cells, and the tra…”
MethodInsertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815 · cited 1×
“full-length transfer vector mRNA for incorporation into vector particles and do not rely on the viral protein Tat for transcription in the producer cells [7].”
BackgroundBurns, J. C., Friedmann, T., Driever, W., Burrascano, M., & Yee, J. K. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8033 · Cited by 1,399 · cited 1×
“This envelope protein allows for the recognition of many target cells and also stabilises the vector particle [4], although other viral proteins have been used.”
BackgroundHowe, S. J., Mansour, M. R., Schwarzwaelder, K., Bartholomae, C., Hubank, M., Kempski, H., Brugman, M. H., Pike-Overzet, K., Chatters, S. J., de Ridder, D., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35798 · Cited by 1,286
Malim, M. H., Hauber, J., Le, S.-Y., Maizel, J. V., & Cullen, B. R. (1989) · Nature · doi:10.1038/338254a0 · Cited by 1,280 · cited 11×
“Importantly, it is plausible to speculate that there may be designs to allow for an all-in-one design to provide the DNA template sequence from the same vector that also expresses the Cas9 protein and guide RNA necessary to enhance this cellular process.”
BackgroundInfluential
Cited by
Novel approaches for vaccine development
Gebre, M. S., Brito, L. A., Tostanoski, L. H., Edwards, D. K., Carfi, A., & Barouch, D. H. (2021) · Cell · doi:10.1016/j.cell.2021.02.030 · Cited by 347
“…(Ads) (Barouch and Picker, 2014; Ertl, 2016), cytomegaloviruses (Barouch and Picker, 2014), adeno‐associated viruses (AAV) (Andari and Grimm, 2020), poxviruses (Conrad and Liu, 2019), herpesviruses (Artusi et al., 2018), and retroviruses (Chen et al., 2018b; Luis, 2020; Stephenson et al., 2016).”
Viral Vectors for the in Vivo Delivery of CRISPR Components: Advances and Challenges
Mengstie, M. A. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.895713 · Cited by 168
“Hence, the transient expression nature of NILVs in dividing cells, combined with their low immunogenicity makes them the most promising vector candidates to be used in clinical applications (Luis, 2020).”
BackgroundChitosan-Based Nanomaterial as Immune Adjuvant and Delivery Carrier for Vaccines
Gong, X., Gao, Y., Shu, J., Zhang, C., & Zhao, K. (2022) · Vaccines · doi:10.3390/vaccines10111906 · Cited by 155
Approved and marketed nanoparticles for disease targeting and applications in COVID-19
Abdellatif, A. A. H., & Alsowinea, A. F. (2021) · Nanotechnology Reviews · doi:10.1515/ntrev-2021-0115 · Cited by 115
Bouazzaoui, A., Abdellatif, A. A. H., Al-Allaf, F. A., Bogari, N. M., Al-Dehlawi, S., & Qari, S. H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020140 · Cited by 98
“The development of non-integrating lentiviral vector (NILVs) [58], which have the capacity to express transgenes transiently in dividing cells or episomes in non-dividing cells and can also be introduced into different cell types, has been a further interesting advancement in the use of lentiviral vectors.”
Background
Metadata
- Authors
- Apolonia, L.
- Affiliations
- King's College London (GB)
- Corresponding author
- Apolonia, Luis
- ORCID
- Apolonia, Luis
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2020-09-29
- Volume
- 12
- Issue
- 10
- Pages
- 1103
- ISSN
- 1999-4915 (ISSN-L)
- PMC
- PMC7600637
- OpenAlex
- W3089800965
- Semantic Scholar
- 324fbc09f8fa809d5a516e0740b3caede616fe8f
- Cited by
- 58
- References
- 113
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 13 · 2023: 9 · 2022: 7 · 2021: 13 · 2020: 1
- FWCI
- 1.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Viruses (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- lentiviral vectors, integrase mutations, insertional mutagenesis, episomal DNA, transgene expression, gene therapy, cell therapy, vaccination, immunotherapy, CRISPR/Cas9 delivery, genome editing
- MeSH terms
- DNA, Viral, Genetic Vectors, Immunotherapy, Plasmids, Genetic Therapy, Gene Expression, Lentivirus, Mutagenesis, Transgenes, Integrases, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Old and the New: Prospects for Non-Integrating Lentiviral Vector Technology. https://app.cochat.ai/papers/10.3390/v12101103
- The paper
- Apolonia, L. (2020). The Old and the New: Prospects for Non-Integrating Lentiviral Vector Technology. Viruses. https://doi.org/10.3390/v12101103
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.